Triple-negative breast cancer (TNBC) has long been considered one of the most difficult types to fight. It is aggressive, often strikes women under age 40, and often resists standard treatments.
Now, a global clinical trial has shown promising results in extending survival for patients with TNBC.
The TROPION-Breast02 trial tested a high-tech treatment called datopotamab deruxtecan (Dato-DXd), already approved for other types of breast cancer.
For patients with advanced TNBC, the drug nearly doubled the time they lived without their cancer worsening — from 5.6 months with standard chemotherapy to 10.8 months with the new therapy. All of the patients had either untreated, locally recurrent, and inoperable cancer or metastatic TNBC for whom immunotherapy was not an option.
Dato-DXd belongs to a class of drugs called antibody-drug conjugates (ADCs). Think of them as biological homing missiles. While traditional chemotherapy acts like a carpet bomb, damaging both healthy and cancerous cells, this new drug uses an antibody to find a specific protein called TROP2 on the surface of cancer cells. Once it latches on, it drops a powerful dose of medicine directly inside the tumor.
“In the TROPION-Breast02 trial, first-line Dato-DXd demonstrated clinically meaningful and significant improvements in progression-free survival and overall survival for these TNBC patients,” lead investigator Dr. Rebecca Dent of the National Cancer Center Singapore said in a news release.
TNBC makes up about 10 to 20 percent of all breast cancer cases. Because it doesn’t respond to hormone therapies, options have historically been limited. While some patients can use immunotherapy, 70 percent of those with TNBC do not qualify for it, leaving them with standard chemotherapy, which often has limited success.
In this trial of 644 patients, Dato-DXd also shrank tumors in 63 percent of patients, compared to only 29 percent for those on chemotherapy. Patients also lived longer overall, with a median survival of 23.7 months. Median means half lived longer, half for a shorter time.
“As a medical oncologist treating triple-negative breast cancer patients for the past 20 years, I am deeply encouraged that this data shows we now have a much-needed new tool to help women affected by this devastating disease,” Dent said.
The study found that Dato-DXd was generally easier on the body than standard chemotherapy. While some patients experienced mouth sores and nausea, fewer people had to stop treatment due to side effects compared to those on traditional chemotherapy, researchers said.
The drug is being fast-tracked for review by the U.S. Food and Drug Administration (FDA) and other global health agencies.
Black women are more likely to die from breast cancer, despite having a lower incidence, and are more often diagnosed with aggressive subtypes like triple-negative breast cancer (TNBC). As mentioned, TNBC accounts for about 10-20 percent of cases and is harder to treat because it lacks targeted treatment options.
New treatments like Dato-DXd, a targeted cancer drug, may offer hope for patients seeking more effective options.
RELATED: Why I Did Clinical Trials for TNBC: “It Very Likely Saved and Extended My Life”
“Aggressive” breast cancer refers to cancers that grow quickly and are more difficult to treat. TNBC is one example — it lacks estrogen, progesterone, and HER2 receptors, meaning standard hormone therapies are not effective.
Because of this, treatment options have historically been limited, making new targeted therapies especially important.
New treatments like Dato-DXd can improve progression-free survival — meaning patients may have more time before their cancer worsens.
For Black patients, who are disproportionately affected by TNBC and other aggressive breast cancers, improved access to these therapies could significantly narrow long-standing survival gaps.
Despite promising advances, many Black patients still face several barriers to accessing new treatments, including:
Addressing these longstanding, systemic barriers is essential to improving outcomes in Black communities.
RELATED: Triple Negative Breast Cancer: What Black Women Need to Know
This study adds to the growing wave of targeted therapies changing how breast cancer is treated. As care becomes more personalized, ensuring equitable access will be key to making sure Black patients benefit from these advances.
New treatments like Dato-DXd are helping improve outcomes for aggressive breast cancers like TNBC. But as this therapy moves through the FDA approval process, early detection, informed decision-making, and equitable access remain critical to improving survival for Black women.
More information
Visit the National Cancer Institute for a deeper look at triple-negative breast cancer and current treatment options.
SOURCES: SingHealth, news release, April 15, 2026; Annals of Oncology, April 3, 2026
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
